Cancer Vaccines Poised to Reach $3 Billion in Sales by 2015

FALLS CHURCH, Va., April 19, 2011 /PRNewswire/ -- Technology Catalysts International (TCI), leading global consultants to the pharmaceutical industry, announced that research on cancer trends and development has identified cancer vaccines as a viable treatment option for a variety of cancers that currently have ineffective treatments.  The potential of the cancer vaccine market is forecast to approach $3 billion in 2015.

With the Medicare advisory committee's recent recommendation to support Dendreon's expensive prostate cancer vaccine, Provenge®, the field of cancer vaccines has received an unprecedented boost.  As a result, many companies are expected to enter this emerging and highly profitable field of preventing, treating, and potentially curing cancer. Prophylactic cancer vaccines, Gardasil® by Merck and Cervarix® by GSK, have already gained worldwide attention with their blockbuster status/potential.

Dr. Joseph Pantginis of Roth Capital Partners, a full service investment banking firm, recently evaluated the BiovaxID® technology from Biovest International and believes that this vaccine will be the next success, even though there are certain risks involved including the path to market for BiovaxID. However, in spite of the risks, Dr. Pantginis feels cancer immunology is coming of age and that BiovaxID can be successful even when two prior idiotype vaccines (developed by Genitope and Favrille) have failed.  According to Dr. Pantginis, there are two main reasons why BiovaxID is believed to have succeeded where the others have failed 1) critical data at the ASH 2010 conference were presented demonstrating that a vaccine against IgM and not igG is the reason for BiovaxID's success and 2) BiovaxID uses the entire idiotype from a patient to manufacture the vaccine whereas Genitope and Favrille used recombinant portions of the idiotype.

The greatest challenges to a successful vaccine development program are seeking the right antigen, selecting the right adjuvant, and developing an effective targeting technology.  Technology Catalysts' newly-released Cancer Vaccines report profiles companies that are developing novel approaches to successfully create effective cancer vaccines and overcome these hurdles.

To leapfrog the development process and enter into strategic alliances, the report provides detailed descriptions of more than 35 companies that have active developments in various approaches to cancer vaccines and are open to strategic alliances. The report also analyzes the current technology and market potential for cancer vaccines and features a pipeline overview, market analysis, and a summary of recent deals associated with cancer vaccines. In addition, the report provides detailed descriptions of novel technologies designed for the development of cancer vaccines. The information is confirmed via company interviews and includes full contact information for easy follow-up and business development opportunities.

A complimentary excerpt of this report is available for download at:

http://www.technology-catalysts.com/pdf/CancerVaccines_Brochure.pdf

About Technology Catalysts International:

Technology Catalysts International ("TCI") was founded in 1979 and provides consulting services in technology transfer and business research. The company specializes in technology licensing, technology assessment, and business intelligence. With a focus on pharmaceuticals, drug delivery, consumer healthcare, and advanced materials/processes, TCI's core consulting services are based on continuous monitoring of technological product development activities on a global basis.  TCI is headquartered in the US and has offices in the UK, Germany, Czech Republic, China, Korea, Japan, India, and Latin America.

Contact:
Ajay Rastogi, Vice President
Technology Catalysts International
Telephone (703) 531-0257
[email protected]
http://www.technology-catalysts.com

SOURCE Technology Catalysts International

Suggested Articles

Data from a 10,000-patient trial showed that people with osteoarthritis taking Novartis' Ilaris had 40% to 47% lower rates of joint replacements.

Immunic's lead asset beat placebo at reducing damage to myelin, which protects nerve fibers, in patients with relapsing multiple sclerosis.

The appointment sees Kobayashi switch from developing Dermira’s anti-IL-13 drug to advancing Aslan’s would-be rival.